Tag: Peter Liese

  • Joe Biden: EU conservative hero

    Joe Biden: EU conservative hero

    [ad_1]

    Press play to listen to this article

    Voiced by artificial intelligence.

    Joe Biden’s European friends may be miffed about his climate law.

    But the U.S. president’s America-first, subsidy-heavy approach has actually gained some grudging — and for a Democrat unlikely — admirers on the Continent: Europe’s conservatives.

    Within the center-right European People’s Party, the largest alliance of parties in the European Parliament, officials are smarting over why their own politicians aren’t taking a page from the Biden playbook.

    Their frustration is homing in on European Commission President Ursula von der Leyen — a putative conservative the EPP itself helped install. Officials fear they have let von der Leyen lead the party away from its pro-industry, regulation-slashing ideals, according to interviews with leading party figures.

    Biden’s law has now brought their grumbling to the surface.

    On Thursday, a wing of EPP lawmakers defected during a Parliament vote over whether to back von der Leyen’s planned response to Biden’s marquee green spending bill, the Inflation Reduction Act (IRA). Their concern: it doesn’t go far enough in championing European industries.

    Essentially, they want it to feel more like Biden’s plan.

    The IRA was an “embarrassment” for Europe, said Thanasis Bakolas, the EPP’s power broker and secretary general. The EU “had all these well-funded policies available. And then comes Biden with his IRA. And he introduces policies that are more efficient, more effective, more accessible to businesses and consumers.”

    A bitter inspiration

    European leaders were blindsided last summer when Biden signed the IRA into law.

    Since then, they have complained loudly that the U.S. subsidies for homegrown clean tech are a threat to their own industries. But for the EPP, ostensibly on the opposite side to Biden’s Democrats, the law is also serving as bitter inspiration.

    “It’s a little bit like in the fairy tale, that someone in the crowd — and this time it wasn’t the boy, it was the Americans — pretty much pointing the finger to the [European] Commission, and saying, ‘Oh, the king is naked?’” said Christian Ehler, a German European Parliament member from the EPP.

    GettyImages 1244434493
    Viewed from bureaucratic, free-trading Brussels, Biden’s climate policy looks more sleek, geopolitically muscular — and, notably for the EPP, more appealing to voters on the right than anything actually coming out of the EPP-led Commission | Oliver Contreras/Getty Images

    Under the EU’s centerpiece climate policy, the European Green Deal, the European Commission, the EU’s policy-making executive arm, has doggedly introduced law after law aimed at squeezing polluters from every angle using tighter regulations or carbon pricing. The goal is to zero out the bloc’s net greenhouse gas emissions by 2050.

    Biden’s IRA approaches the same goal by different means. It is laden with voter- and industry-friendly tax breaks and made-in-America requirements. Viewed from bureaucratic, free-trading Brussels, Biden’s climate policy looks more sleek, geopolitically muscular — and, notably for the EPP, more appealing to voters on the right than anything actually coming out of the EPP-led Commission.

    For some, the sense of betrayal isn’t directed at Washington, but inward.

    “We learned that we lost track for the last two years on the deal part of the Green Deal,” said Ehler, who is using his seat on Parliament’s powerful Committee on Industry, Research and Energy to push for fewer climate burdens on industry. “We are in the midst of the super regulation.”

    The irony is that Biden and the Democrats probably wouldn’t have chosen this path were it not for Republicans’ decades-long refusal to move any form of climate regulation through Congress.

    The IRA was a product of political necessity, shaped to suit independent-minded Democratic senators such as Joe Manchin of coal-heavy West Virginia. If Biden and his party had their druthers, Biden’s climate policy might have looked far more like the Brussels model.

    Let’s get political

    As party boss, Bakolas is preparing the platform on which the EPP — a pan-European umbrella group of 81 center-right parties — will campaign for the 2024 EU elections.

    He is also flirting with an alliance with the far right, meaning the center-right and center-left consensus that has dominated climate policy in Brussels could break up. Bakolas advocates “a more political approach.”

    “We need to do the same [as the U.S.], with the same tenacity and determination,” he said.

    One big problem: It’s hard for the European Union, which doesn’t control tax policy, to match the political eye-candy of offering cashback for electric Hummers (something Americans can now claim on their taxes).

    “Can Europe, this institutional arrangement in Brussels … act as effortlessly and seamlessly as the American administration? No, because it’s a difficult exercise for Europe to reach a decision … but it’s an exercise we need to do,” said Bakolas.

    GettyImages 1246737828
    Within the center-right European People’s Party, the largest alliance of parties in the European Parliament, officials are smarting over why their own politicians aren’t taking a page from the Biden playbook | Kenzo Tribouillard/AFP via Getty Images

    In other words, the EPP is looking to emulate Biden’s law — at least in spirit, if not in legalese.

    The conservative thinking is beginning to coalesce into a few main themes: slowing down green regulation they feel burden industry; using sector-specific programs to help companies reinvest their profits into cleaning up their businesses; and slashing red tape they say slows already clean industries from getting on with the job.

    EPP lawmaker Peter Liese said he had been “desperately calling” for these red-tape-slashing measures. He was glad to see some in von der Leyen’s contested IRA response plan. But Liese and the EPP want more.

    “We can have an answer of the two crises, the two challenges, that we have: the climate crisis and challenge for our economy, including the IRA,” said Liese.

    Green groups and left-wing lawmakers argue the EPP is simply using the IRA and Europe’s broader economic woes as a smokescreen to cover a broad retreat from the Green Deal. In recent months the party has blocked, or threatened to block, a host of green regulations proposed by the Commission.

    “This is like trying to put on the ballroom shoes of your grandfather and trying to do a 100-meter sprint,” Green MEP Anna Cavazzini told Parliament on Wednesday.

    Bakolas rejected that.

    He said the party had finally woken up to the need to set a climate agenda that better reflected its own, center-right, free-market ideals.

    “What the IRA did,” he said, “is to ring an alarm bell.”



    [ad_2]
    #Joe #Biden #conservative #hero
    ( With inputs from : www.politico.eu )

  • Europe is running out of medicines

    Europe is running out of medicines

    [ad_1]

    Press play to listen to this article

    Voiced by artificial intelligence.

    When you’re feeling under the weather, the last thing you want to do is trek from pharmacy to pharmacy searching for basic medicines like cough syrup and antibiotics. Yet many people across Europe — faced with a particularly harsh winter bug season — are having to do just that.

    Since late 2022, EU countries have been reporting serious problems trying to source certain important drugs, with a majority now experiencing shortages. So just how bad is the situation and, crucially, what’s being done about it? POLITICO walks you through the main points.

    How bad are the shortages?

    In a survey of groups representing pharmacies in 29 European countries, including EU members as well as Turkey, Kosovo, Norway and North Macedonia, almost a quarter of countries reported more than 600 drugs in short supply, and 20 percent reported 200-300 drug shortages. Three-quarters of the countries said shortages were worse this winter than a year ago. Groups in four countries said that shortages had been linked to deaths.

    It’s a portrait backed by data from regulators. Belgian authorities report nearly 300 medicines in short supply. In Germany that number is 408, while in Austria more than 600 medicines can’t be bought in pharmacies at the moment. Italy’s list is even longer — with over 3,000 drugs included, though many are different formulations of the same medicine.

    Which medicines are affected?

    Antibiotics — particularly amoxicillin, which is used to treat respiratory infections — are in short supply. Other classes of drugs, including cough syrup, children’s paracetamol, and blood pressure medicine, are also scarce.

    Why is this happening?

    It’s a mix of increased demand and reduced supply.

    Seasonal infections — influenza and respiratory syncytial virus (RSV) first and foremost — started early and are stronger than usual. There’s also an unusual outbreak of throat disease Strep A in children. Experts think the unusually high level of disease activity is linked to weaker immune systems that are no longer familiar with the soup of germs surrounding us in daily life, due to lockdowns. This difficult winter, after a couple of quiet years (with the exception of COVID-19), caught drugmakers unprepared.

    Inflation and the energy crisis have also been weighing on pharmaceutical companies, affecting supply.

    Last year, Centrient Pharmaceuticals, a Dutch producer of active pharmaceutical ingredients, said its plant was producing a quarter less output than in 2021 due to high energy costs. In December, InnoGenerics, another manufacturer from the Netherlands, was bailed out by the government after declaring bankruptcy to keep its factory open.

    h 57672624
    Commissioner Stella Kyriakides wrote to Greece’s health minister asking him to take into consideration the effects of bans on third countries | Stephanie Lecocq/EPA-EFE

    The result, according to Sandoz, one of the largest producers on the European generics market, is an especially “tight supply situation.” A spokesperson told POLITICO that other culprits include scarcity of raw materials and manufacturing capacity constraints. They added that Sandoz is able to meet demand at the moment, but is “facing challenges.”

    How are governments reacting?

    Some countries are slamming the brakes on exports to protect domestic supplies. In November, Greece’s drugs regulator expanded the list of medicine whose resale to other countries — known as parallel trade — is banned. Romania has temporarily stopped exports of certain antibiotics and kids’ painkillers. Earlier in January, Belgium published a decree that allows the authorities to halt exports in case of a crisis.

    These freezes can have knock-on effects. A letter from European Health Commissioner Stella Kyriakides addressed to Greece’s Health Minister Thanos Plevris asked him to take into consideration the effects of bans on third countries. “Member States must refrain from taking national measures that could affect the EU internal market and prevent access to medicines for those in need in other Member States,” wrote Kyriakides.

    Germany’s government is considering changing the law to ease procurement requirements, which currently force health insurers to buy medicines where they are cheapest, concentrating the supply into the hands of a few of the most price-competitive producers. The new law would have buyers purchase medicines from multiple suppliers, including more expensive ones, to make supply more reliable. The Netherlands recently introduced a law requiring vendors to keep six weeks of stockpiles to bridge shortages, and in Sweden the government is proposing similar rules.

    At a more granular level, a committee led by the EU’s drugs regulator, the European Medicines Agency (EMA), has recommended that rules be loosened to allow pharmacies to dispense pills or medicine doses individually, among other measures. In Germany, the president of the German Medical Association went so far as to call for the creation of informal “flea markets” for medicines, where people could give their unused drugs to patients who needed them. And in France and Germany, pharmacists have started producing their own medicines — though this is unlikely to make a big difference, given the extent of the shortfall.

    Can the EU fix it?

    In theory, the EU should be more ready than ever to tackle a bloc-wide crisis. It has recently upgraded its legislation to deal with health threats, including a lack of pharmaceuticals. The EMA has been given expanded powers to monitor drug shortages. And a whole new body, the Health Emergency Preparedness and Response Authority (HERA) has been set up, with the power to go on the market and purchase drugs for the entire bloc.

    But not everyone agrees that it’s that bad yet.

    Last Thursday, the EMA decided not to ask the Commission to declare the amoxycillin shortage a “major event” — an official label that would have triggered some (limited) EU-wide action— saying that current measures are improving the situation.

    A European Medicines Agency’s working group on shortages could decide on Thursday whether to recommend that the Commission declares the drug shortages a “major event” — an official label that would trigger some (limited) EU-wide action. An EMA steering group for shortages would have the power to request data on drug stocks of the drugs and production capacity from suppliers, and issue recommendations on how to mitigate shortages.

    At an appearance before the European Parliament’s health committee, the Commission’s top health official, Sandra Gallina, said she wanted to “dismiss a bit the idea that there is a huge shortage,” and said that alternative medications are available to use.

    And others believe the situation will get better with time. “I think it will sort itself out, but that depends on the peak of infections,” said Adrian van den Hoven, director general of generics medicines lobby Medicines for Europe. “If we have reached the peak, supply will catch up quickly. If not, probably not a good scenario.”

    Helen Collis and Sarah-Taïssir Bencharif contributed reporting.



    [ad_2]
    #Europe #running #medicines
    ( With inputs from : www.politico.eu )